SCHEMBL5237488

SCHEMBL5237488

CN(CCN(C)c1ccc(Br)cn1)c1ccc(Br)cn1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 5/20 0.60
HCAR3 P49019 1/20 0.45
EGFR P00533 3/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
POLB P06746 2/20 0.37
TAAR1 Q96RJ0 1/20 0.36
AOC3 Q16853 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SSTR2 P30874 1/20 0.35
SSTR4 P31391 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1432671 0.90 GBA1 (0.59) GBA1HCAR3EGFRPKMALDH1A1
SCHEMBL5255404 0.89 GBA1 (0.53) GBA1HCAR3EGFRALDH1A1NPC1
SCHEMBL31217157 0.87 GBA1 (0.56) GBA1HCAR3EGFRNPC1RAB9A
SCHEMBL2256335 0.87 GBA1 (0.51) GBA1HCAR3EGFRPKMHRH3
SCHEMBL1433090 0.86 GBA1 (0.69) GBA1HCAR3ALDH1A1NPC1MAPT
SCHEMBL10653784 0.86 GBA1 (0.57) GBA1HCAR3EGFRPKMALDH1A1
SCHEMBL5253357 0.86 GBA1 (0.50) GBA1HCAR3EGFRALDH1A1KDM4E
SCHEMBL21841697 0.83 GBA1 (0.47) GBA1HCAR3EGFRALDH1A1NPC1
SCHEMBL22085994 0.83 GBA1 (0.47) GBA1HCAR3EGFRPKMALDH1A1
SCHEMBL31217283 0.81 GBA1 (0.53) GBA1HCAR3EGFRALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403250-B1 BIS(5-ARYL-2-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-7196101-B2 Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases KOWA CO., LTD (JP) 2007-03-27 US disclosed
EP-1403250-A1 BIS(5-ARYL-2-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-6706703-B2 BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES KOWA CO., LTD. (JP) 2004-03-16 US disclosed
US-20030027814-A1 Bis(5-aryl-2-pyridyl) derivatives KOWA CO., LTD. (JP) 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027814-A1 Bis(5-aryl-2-pyridyl) derivatives AHR, PAH, H1-0 GBA1 4244/4885HCAR3 2239/4885EGFR 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.